Outcome of treatment changes in patients with drug-resistant chronic epilepsy: A tertiary center experience.

BACKGROUND: Previous studies suggest that changing patients' anti-epileptic drug regimen can reduce the frequency of seizures. The approval of new anti-epileptic drugs with different modes of action during the last decades has provided multiple options for the treatment of epilepsy, although the efficacy of these new drugs is controversial. We aimed to determine the effects of adding or changing to a previously untried anti-epileptic drug, including recently approved drugs, on the frequency of seizures in patients with drug-resistant epilepsy. METHODS: We analyzed treatment changes in drug-resistant patients at our outpatient clinic between 2010 and 2015. We classified patients' frequency of seizures after changes as freedom from seizures, ≥50% reduction, <50% reduction, no change, increase in seizures <50% or increase in seizures ≥50%. RESULTS: We analyzed 189 drug changes in 144 consecutive drug-resistant patients followed up for at least 6 months after the change; 138 changes involved administering newly marketed drugs: lacosamide (n=65), perampanel (n=30), eslicarbazepine (n=29), and retigabine (n=14). Changes resulted in freedom from seizures in 20 (13.9%) patients and in ≥50% decrease in frequency in 55 (38.2%). The drugs most commonly associated with significant improvement (freedom from seizures or ≥50% reduction) were lacosamide (39.3%), clobazam (11.2%), and levetiracetam (11.2%). CONCLUSIONS: In patients with drug-resistant epilepsy, sequential changes increase the possibility of seizure control, and newer anti-epileptic drugs offer additional options for effective changes. Best combinations must be chosen taking into account drug, epilepsy and patient features.

[Results of vagal nerve stimulation in patients with pharmacoresistant epilepsy in a national epilepsy referral centre]. / Resultados de la estimulacion del nervio vago en pacientes con epilepsia farmacorresistente en un centro de referencia nacional de epilepsia.

AIM: To describe clinical results and complications derived from vagal nerve stimulation therapy in drug resistant epileptic patients unsuitable for other surgical treatments, since the first implant in an epilepsy national referral centre. PATIENTS AND METHODS: A retrospective analysis of the patients implanted in our centre was held. Data related to baseline characteristics of their epilepsy and therapy complications was collected. RESULTS: 32 new implants in 31 patients are included, mean age of 34 years, 29.3 years of disease evolution, three anti-epileptic drugs at surgery and a postoperative follow-up of 4.03 years. Complex partial seizures types (71.9%) and cryptogenic aetiology (59.4%) were the most frequent. 75% of patients hadn't history of previous epilepsy surgery. 43.8% of patients had a seizure frequency improvement above 50%, with a better response in patients with complex partial seizures (p = 0.22) and cryptogenic aetiology. None statistical significance was found between antiepileptic drugs and seizure frequency. Dysphonia, hoarseness and dysphagia, mostly transient, were the side effects registered. There was an asystole during surgery, completely recovered. One device was replaced due to hardware rupture after a seizure related trauma, one had to be adjusted due to a previous vocal cord paresis, and one dysfunctioning device was removed. In 84.4% the tolerance was excellent. CONCLUSIONS: Vagal nerve stimulation is an effective treatment for significant seizure frequency improvement of resistant patients untreatable with other medical or surgical treatments. Further studies are needed to predict the individual response of each patient to therapy and optimizing indications, therefore contributing to cost/benefit optimization.

TITLE: Resultados de la estimulacion del nervio vago en pacientes con epilepsia farmacorresistente en un centro de referencia nacional de epilepsia.Objetivos. Describir los resultados clinicos y complicaciones derivados de la estimulacion vagal en pacientes con epilepsia farmacorresistente no tributaria de otras modalidades de tratamiento quirurgico, desde el primer implante en un centro de referencia nacional. Pacientes y metodos. Se realizo un analisis retrospectivo de los pacientes implantados en nuestro centro y se extrajeron datos relativos a las caracteristicas basales de su epilepsia y complicaciones derivadas. Resultados. Se incluyeron 32 nuevos implantes en 31 pacientes, con una edad media de 34 años, evolucion de enfermedad de 29,3 años, tres farmacos antiepilepticos prequirurgicos y 4,03 años de seguimiento. Las crisis parciales complejas (71,9%) y criptogenicas (59,4%) fueron el tipo y la etiologia de crisis mas frecuentes. El 75% no tenia antecedentes quirurgicos de epilepsia. Un 43,8% presento mejoria igual o superior al 50%, mayor en las epilepsias parciales complejas (p = 0,22) y la etiologia criptogenica. No se hallo asociacion estadistica entre ajustes de medicacion y frecuencia de las crisis. Los efectos secundarios encontrados fueron disfonia, ronquera y disfagia transitorias, y una asistolia intraoperatoria recuperada. Se realizo un recambio por ruptura de hardware postraumatica. Un paciente con paresia preexistente de cuerda vocal presento estridor laringeo que requirio ajuste de intensidad, y se produjo una retirada del sistema por disfuncion. En el 84,4%, la tolerancia fue excelente. Conclusiones. Constituye un tratamiento efectivo para mejorar significativamente la frecuencia de crisis de los pacientes farmacorresistentes y con contraindicacion para otras modalidades de tratamiento quirurgico. Se precisan futuros estudios para predecir la respuesta individual de cada paciente, optimizar las indicaciones y mejorar la relacion coste/beneficio.